{"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"FG000","title":"Pembrolizumab + Lenalidomide + Dexamethasone"},{"description":"Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.","id":"FG001","title":"Lenolidomide + Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Final Disposition Unknown"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"11"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"29"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Screen Failure"},{"reasons":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"88"}],"type":"Study Terminated at Selected Sites"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"154"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"148"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"154"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Note: Due to administrative reasons (a noncompliant site), 2 participants in the Pembrolizumab plus SOC arm and one participant in the SOC arm, were recorded as \"Ongoing in Trial\" in the CSR Disposition Table and \"Final Disposition Unknown\" here.","recruitmentDetails":"This study was conducted at 140 centers in 15 countries. The database cutoff date was August 3, 2020."}